NAMES IN THE NEWS 100 mg/mL Antimicrobial Injectable Solution
For Subcutaneous Use In Beef Cattle, Non-Lactating Dairy Cattle And Swine Only
BRIEF SUMMARY: Before using Baytril® 100, please consult the product insert, a sum- mary of which follows: CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. Federal (U.S.A.) law prohibits the extra-label use of this drug in food- producing animals. PRODUCT DESCRIPTION: Each mL of Baytril® 100 contains 100 mg of enrofloxacin. Excipients are L-arginine base 200 mg, n-butyl alcohol 30 mg, benzyl alcohol (as a pre- servative) 20 mg and water for injection q.s. INDICATIONS: Cattle - Single-Dose Therapy: Baytril® 100 is indicated for the treat- ment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida,Histophilus somni and Mycoplasma bovis in beef and non-lactating dairy cattle; and for the control of BRD in beef and non-lactating dairy cattle at high risk of developing BRD associated with M. haemolytica, P. multocida, H. somni andM. bovis. Cattle - Multiple-Day Therapy:Baytril®100 is indicated for the treat- ment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni in beef and non-lactating dairy cattle. Swine: Baytril®100 is indicated for the treatment and control of swine respiratory disease (SRD) associated with Actinobacillus pleuropneu- moniae, Pasteurella multocida, Haemophilus parasuis, Streptococcus suis, Bordetella bronchisepticaand Mycoplasma hyopneumoniae.
Not For Use In Female Dairy Cattle 20 Months Of Age Or Older Or In Calves To Be Processed For Veal
RESIDUE WARNINGS: Cattle: Animals intended for human consumption must not be slaughtered within 28 days from the last treatment. This product is not approved for female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal. Swine: Animals intended for human consumption must not be slaughtered within 5 days of receiving a single-injection dose.
HUMAN WARNINGS: For use in animals only. Keep out of the reach of children. Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes. In case of dermal contact, wash skin with soap and water. Consult a physician if irritation per- sists following ocular or dermal exposures. Individuals with a history of hypersensitivity to quinolones should avoid this product. In humans, there is a risk of user photosensitization within a few hours after excessive exposure to quinolones. If excessive accidental expo- sure occurs, avoid direct sunlight. For customer service or to obtain product information, including a Material Safety Data Sheet, call 1- 800-633-3796. For medical emergencies or to report adverse reac- tions, call 1-800-422-9874. PRECAUTIONS: The effects of enrofloxacin on cattle or swine reproductive perform- ance, pregnancy and lactation have not been adequately determined. The long-term effects on articular joint cartilage have not been deter- mined in pigs above market weight. Subcutaneous injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter. Baytril® 100 contains different excipients than other Baytril® prod- ucts. The safety and efficacy of this formulation in species other than cattle and swine have not been determined. Quinolone-class drugs should be used with caution in animals with known or suspected Central Nervous System (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to convulsive seizures. Quinolone-class drugs have been shown to produce erosions of cartilage of weight-bear- ing joints and other signs of arthropathy in immature animals of various species. See Animal Safety section for additional information. ADVERSE REACTIONS: No adverse reactions were observed during clinical trials. ANIMAL SAFETY: In cattle safety studies, clinical signs of depression, incoordination and muscle fasciculation were observed in calves when doses of 15 or 25 mg/kg were administered for 10 to 15 days. Clinical signs of depres- sion, inappetance and incoordination were observed when a dose of 50 mg/kg was administered for 3 days. An injection site study conducted in feeder calves demonstrated that the formulation may induce a tran- sient reaction in the subcutaneous tissue and underlying muscle. In swine safety studies, incidental lameness of short duration was observed in all groups, including the saline-treated controls. Muscu- loskeletal stiffness was observed following the 15 and 25 mg/kg treatments with clinical signs appearing during the second week of treatment. Clinical signs of lameness improved after treatment ceased and most animals were clinically normal at necropsy. An injection site study conducted in pigs demonstrated that the formula- tion may induce a transient reaction in the subcutaneous tissue. U.S. Patent No. 5,756,506
Bayer, the Bayer Cross, and Baytril are registered trademarks of Bayer. NADA 141-068, Approved by FDA Bayer HealthCare LLC, Animal Health Division Shawnee Mission, Kansas 66201 U.S.A.
GHG050714 Baytril®100
©2012 Bayer HealthCare LLC 17688
November, 2012 80908653, R.3
James E. Herring, Amarillo, has been selected to receive the prestigious National Golden Spur Award for 2014. Herring will receive the award Sept.
20, 2014, at the National Ranching Heritage Center on the Texas Tech Uni- versity campus. The accolade is a joint recognition by some of the industry’s leading organizations: American Quarter Horse Association; National Cattle- men’s Foundation; Ranching Heritage Association; Texas and Southwestern Cattle Raisers Association; Texas Cattle Feeders Association; and Texas Farm Bureau. Congratulations to these TSCRA members who are part of the Texas Agriculture Lifetime Leadership (TALL) class of 2014 to 2016: Jorge Luis
Alvarez Jr., Santa Elena; Wes Chandler, Garrison; Steven Kahla, Waller; and Travis Thorne, Bowie. The Noble Foundation board of trustees has approved the promotion and appointment of Professor Zengyu Wang, Ph.D., to senior vice president and
director of the Forage Improvement Division. “Dr. Wang is one of our most respected researchers,” said Bill Buckner, president and CEO of the Noble Foundation. “He brings a strong sense of leadership and a willingness to serve. He is an advocate for the Noble Foundation and agriculture. Dr. Wang is the clear choice to lead this division into the future.” The National Cowgirl Museum and Hall of Fame announces the 2014 Na- tional Cowgirl Hall of Fame Inductees: Jean Cates and Sue Cunningham,
C-Bar-C Chuckwagon; Shirley Lucas Jauregui; May Owen, M.D. (1891-1988); and Frances Kavanaugh Hecker (1915-2009), the “Cowgirl of the Typewriter.” Heritage Land Bank is pleased to announce that Yaziri Orrostieta has joined the ag-lending cooperative as the new marketing director. She will be based in the corporate offi ce in Tyler.
INDUSTRY NEWS
National Dove Hunter Survey Findings Released
T
HE RECENTLY RELEASED FINDINGS OF A NATIONAL Dove Hunter Survey will help managers
better understand the opinions of this impor- tant hunting community at a national level. Last year, the survey was sent to randomly
selected hunters in the 40 states with dove hunting seasons. The large sample of 800 per state on average ensured that most of the survey results are applicable at the national, regional, and state levels. Of the 30,382 surveys successfully delivered, 12,631 hunters responded — earning a 41.6 percent response rate. Find the full survey results and more information about dove hunting at
http://bit.ly/DoveHunterSurvey.
Picture © Texas Parks and Wildlife Department 38 The Cattleman September 2014
thecattlemanmagazine.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116